IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer

Reuters11-19

IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer

IceCure Medical Ltd. has received significant regulatory approvals for its cryoablation technologies. The company announced that its ProSense® system has been granted FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and above and patients not suitable for surgery, marking a major milestone that opens the U.S. market for its minimally invasive technology. In addition, ProSense® and its cryoprobes are now cleared for commercial sale in Switzerland for use in the treatment of malignant or benign tissue in the breast, lung, liver, kidney, and musculoskeletal system, including palliative care. Furthermore, Israel has granted regulatory approval for IceCure's next-generation XSense™ Cryoablation System for breast cancer and other indications, while XSense™ and its cryoprobes have received a Notice of Allowance for patents in both the U.S. and Japan, strengthening the company's intellectual property portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO28579) on November 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584944461?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584944461","market":"us","top_or_hot":-1,"title":"IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> has received significant regulatory approvals for its cryoablation technologies. The company announced that its ProSense® system has been granted FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and above and patients not suitable for surgery, marking a major milestone that opens the U.S. market for its minimally invasive technology. In addition, ProSense® and its cryoprobes are now cleared for commercial sale in Switzerland for use in the treatment of malignant or benign tissue in the breast, lung, liver, kidney, and musculoskeletal system, including palliative care. Furthermore, Israel has granted regulatory approval for IceCure's next-generation XSense™ Cryoablation System for breast cancer and other indications, while XSense™ and its cryoprobes have received a Notice of Allowance for patents in both the U.S. and Japan, strengthening the company's intellectual property portfolio.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO28579) on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-19 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICCM\">IceCure Medical Ltd.</a> has received significant regulatory approvals for its cryoablation technologies. The company announced that its ProSense® system has been granted FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and above and patients not suitable for surgery, marking a major milestone that opens the U.S. market for its minimally invasive technology. In addition, ProSense® and its cryoprobes are now cleared for commercial sale in Switzerland for use in the treatment of malignant or benign tissue in the breast, lung, liver, kidney, and musculoskeletal system, including palliative care. Furthermore, Israel has granted regulatory approval for IceCure's next-generation XSense™ Cryoablation System for breast cancer and other indications, while XSense™ and its cryoprobes have received a Notice of Allowance for patents in both the U.S. and Japan, strengthening the company's intellectual property portfolio.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO28579) on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL6yRvDb:1","article_id":"2584944461","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584944461","pubTimestamp":1763560493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IceCure Medical Ltd. has received significant regulatory approvals for its cryoablation technologies. The company announced that its ProSense system has been granted FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and above and patients not suitable for surgery, marking a major milestone that opens the U.S. market for its minimally invasive technology. In addition, ProSense and its cryoprobes are now cleared for commercial sale in Switzerland for use in the treatment of malignant or benign tissue in the breast, lung, liver, kidney, and musculoskeletal system, including palliative care. Furthermore, Israel has granted regulatory approval for IceCure's next-generation XSense Cryoablation System for breast cancer and other indications, while XSense and its cryoprobes have received a Notice of Allowance for patents in both the U.S. and Japan, strengthening the company's intellectual property portfolio.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ICCM":"IceCure Medical Ltd."},"translate_title":"IceCure Medical获得FDA批准ProSense冷冻消融系统治疗低风险乳腺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCM":0.9},"content_text":"IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer\n    \n\nIceCure Medical Ltd. has received significant regulatory approvals for its cryoablation technologies. The company announced that its ProSense® system has been granted FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and above and patients not suitable for surgery, marking a major milestone that opens the U.S. market for its minimally invasive technology. In addition, ProSense® and its cryoprobes are now cleared for commercial sale in Switzerland for use in the treatment of malignant or benign tissue in the breast, lung, liver, kidney, and musculoskeletal system, including palliative care. Furthermore, Israel has granted regulatory approval for IceCure's next-generation XSense™ Cryoablation System for breast cancer and other indications, while XSense™ and its cryoprobes have received a Notice of Allowance for patents in both the U.S. and Japan, strengthening the company's intellectual property portfolio.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO28579) on November 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584944461","isCrawlerRequest":true}